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Inhibitorysical and structural studies of the cytochrome (cyt) bc1 complex in the past have
led to the formulation of the “protonmotive Q-cycle”mechanism for electron and proton transfer in this vitally
important complex. The key step of this mechanism is the separation of electrons during the oxidation of a
substrate quinol at theQP sitewith both electrons transferred simultaneously to ISP and cytbLwhen the extrinsic
domain of ISP (ISP-ED) is located at the b-position. Pre-steady state fast kinetic analysis of bc1 demonstrates that
the reduced ISP-EDmoves to the c1-position to reduce cyt c1 only after the reduced cyt bL is oxidized by cyt bH.
However, the question of how the conformational switch of ISP-ED is initiated remains unanswered. The results
obtained from analysis of inhibitory efﬁcacy and binding afﬁnity of two types of QP site inhibitors, Pm and Pf,
under various redox states of the bc1 complex, suggest that the electron transfer from heme bL to bH is the
driving force for the releasing of the reduced ISP-ED from the b-position to c1-position to reduce cyt c1.
Published by Elsevier B.V.1. Introduction
The cytochrome bc1 complex (also known as ubiquinol-cytochrome
c reductase, complex III or bc1) is an important segment of the electron
transfer chain of mitochondria and many respiratory and photosyn-
thetic bacteria [1]. It catalyzes electron transfer from ubiquinol to cyt c
with concomitant translocation of protons across the membrane to
generate a proton gradient and membrane potential for ATP synthesis
[2]. Intensive biochemical and biophysical studies in the past decades
on this complex [3,4] have led to the formulation of the “protonmotive
Q-cycle” mechanism for electron and proton transfer in this complex
[5,6], which deﬁnes two separate quinol reaction sites: one for quinol
oxidation (Qo or QP) and the other for quinone reduction (Qi or QN). The
key step in the Q-cycle mechanism is the bifurcated electron transfer
(ET) in the oxidation of ubiquinol at the QP site (Fig. 1). There are two
mechanisms proposed for the bifurcated oxidation of ubiquinol, the
sequential and the concerted mechanisms. In the sequential mechan-luster of ISP; bL, low-potential
complex; cyt, cytochrome; ET,
ndria; ISP, iron–sulfur protein;
imetry; MOAS, (E)-β-methox-
rmation of ISP-ED; Pm, QP site
M, transmembrane; UHDBT, 5-
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.V.ism, it was postulated that the ﬁrst electron of ubiquinol is transferred
to the high-potential chain, consisting of the iron–sulfur protein (ISP)
and cyt c1. The resulted ubisemiquinone then passes its electron
through the qlow-potential chainq, consisting of cyt bL and bH, to
reduce ubiquinone or ubisemiquinone bound at the QN site. In the
concertedmechanism, two electrons of ubiquinol are transferred to ISP
and cyt bL simultaneously from a transient ternary complex of ISP-
QH2-cyt bwhen ISP-ED is located at the b-position. The reduced ISP-ED
moves to the c1-position to reduce cyt c1 after reduced heme bL is
oxidized by heme bH [7]. Both mechanisms ensure a proton pumping
efﬁciency of two protons per electron transferred to the substrate cyt c.
2. The Q-cycle mechanism is supported by crystal structures
Various QN or QP site speciﬁc inhibitor resistant mutations of bc1
complexes have been mapped to the sequence of cyt b subunit [8].
Sequence analyses of these mutations not only are consistent with the
two sites hypothesis of theQ-cyclemechanismbut also led to the correct
prediction of eight transmembrane (TM) segments for the cyt b subunit
[9]. The presence of the two separated quinone/quinol binding domains
is directly observed in X-ray crystal structures of bc1 complexes from
mitochondria of various organisms [10–13], which placed the two sites
on the opposite side of the membrane (Fig. 2). The QN site is near the
heme bH on themitochondrialmatrix side and theQP site is located near
the 2Fe2S cluster of the ISP subunit on the inter-membrane space side
(IMS). Both sites residewithin the cyt b subunit. Crystal structures show
that the cyt c1 subunit has a large globular N-terminal soluble domain
localized to the IMS and connected to a C-terminal TM segment. The
Fig. 1. The protonmotive Q-cycle mechanism. (A) Sequential bifurcated oxidation of
quinol at Qp site. Ubiquinol bound in cyt b is ﬁrst oxidized by ISP to generate a
ubisemiquinone radical to reduce cyt bL. (B) Concerted bifurcated oxidation of ubiquinol
at Qp QP site. Bifurcated oxidation of ubiquinol at QP site by ISP and cyt bL takes place
simultaneously with no generation of ubisemiquinone radical at the QP site.
Fig. 2. Dimeric structural model for the three essential subunits of the bc1 complex. Two
symmetry-related cyt b subunits are shown (green and light green). The eight TM
helices of cyt b are denoted with letters from A to H. Helices A to E form one bundle in
which the two b-type hemes (bL and bH in ball-and-stick models) reside; helices F to H
form the other bundle. The ISP subunit (yellow and red for the symmetry pair) has an
extrinsic soluble domainwith a 2Fe2S cluster at its tip, connecting to a TM segment by a
ﬂexible neck. The extrinsic domain of cyt c1 subunit (blue and magenta for the
symmetry pair) with its heme group is rigidly attached to its TM helix. The locations for
the two active sites (QP and QN) per monomer in cyt b are labeled. The surface
depression in cyt b at the inter-membrane space (IMS) side of the membrane is labeled
as the ISP-docking crater.
Fig. 3. Arrangement of prosthetic groups in the dimeric bc1 complex. The bL, bH, and c1
heme groups are shown as the ball-and-stick models, whereas the 2Fe2S clusters are
depictedasCPKmodels. Carbonatomsare colored inyellow,nitrogen inblue, oxygen inred,
sulfur in light yellow, and iron in brown. Distances between redox centers are indicated.
The anomalous difference Fourier map is contoured at 4.5σ and shown as red wire cage.
Difference fourier maps calculated between various inhibitor-bound and native crystal are
shown as blue (MOAS), green (stigmatellin), or magenta (antimycin A) cage, respectively.
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rigid. In contrast, the ISP subunit has an N-terminal TM segment and a
C-terminal globular, extrinsic or head domain of ISP (ISP-ED) connected
by a ﬂexible linker (hinge or neck). As it turns out, the ﬂexibility of the
ISP linker is required for function of the bc1 complex [14].
3. The mobility of the extrinsic domain of ISP is required for
bc1 function
The ﬁrst crystal structure from bovine bc1 in the tetragonal space
group (I4122) shows a longer than expected distance of 31 Å between
the cyt c1 heme iron (Fig. 3) and the 2Fe2S cluster of ISP and a
particularly disordered ISP-ED. Base on these observations, the authors
suggested a possible motion of the ISP-ED to bridge the electron
transfer from the ISP subunit to cyt c1 [10]. Structures of mitochondrial
bc1 from chicken and from bovine heart crystallized in various space
groups show at least three different localizations for ISP-ED [11,12],
leading to the proposed mechanism by Zhang et al. on the ET between
the ISP and cyt c1 through the domain movement of ISP-ED [12] and
the deﬁnition of various ISP-ED binding positions in the bc1 complex
[11]. The b-position is deﬁned as ISP-ED bound to the QP site; the c1-
position is referred to the ISP-ED position close to the c1 subunit; the
intermediate-site localized the ISP-ED in between the b- and c1-sites.
Table 1 summarizes information from earlier crystal structures of cyt
bc1 complex from various sources in the presence and absence of
inhibitors, including inhibitor types, measured distances between
2Fe2S cluster and c1 heme iron, as well as PDB codes. However, in all
these initial structural studies, the question of how exactly the
electrons bifurcate at the QP site was not addressed.
Table 1
Crystal structures of mitochondrial bc1 complexes, space groups, and different locations
of the ISP-ED as determined from crystal structures
Year Species Space
group
Bound inhibitors Distance
(Å)⁎
Res.
(Å)†
PDB Author Ref.
1997 Beef I4122 Antimycin A and
myxothizaol
31 2.9 1QCR Xia et
al.
[10]
1998 Chicken P212121 Stigmatellin 21.3 3.7 1BCC Zhang
et al.
[12]
1998 Beef P6522 None 15.5 3.0 1BE3 Iwata
et al.
[11]
1998 Beef P65 None 27.5 3.0 1BGY Iwata
et al.
[11]
2000 Yeast C2 Stigmatellin 31 2.3 1EZV Hunte
et al.
[13]
⁎Distance between 2Fe2S cluster of ISP and heme iron of cyt c1.
†Resolution.
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by various groups in order to validate the proposed requirement for the
ISP-ED movement. Changes made to the amino acid sequence of the
hinge region of ISP, designed to alter the ﬂexibility of the hinge to various
degrees, invariably affect the function of the bc1 [14–19]. Cross-linking
between the ISP-ED and cyt b subunits inactivate the enzyme [20]. These
experimentsdemonstrate the importanceof the ISPmobility for function.
4. The extrinsic domain of ISP can undergo a binary
conformational switch
Inhibitors of bc1 complex targeting the QP site had previously been
categorized into three subclasses on the basis of spectroscopic effects
to the bL heme of cyt b subunit and the 2Fe2S cluster of ISP, as well as
changes in redox potentials of the ISP upon their binding [21]. Initial
analyses of bovine bc1 crystalswith bound inhibitors such as antimycin
A, myxothiazol, MOAS, and stigmatellin deﬁned the physical locations
of QN and QP sites [10,12,13,22]. Further analyses of bc1 crystals in the
tetragonal space group (I4122), in which the ISP-ED is less restricted in
motion by crystal contacts, revealed that Class Ia inhibitors such as
myxothiazol and β-methoxyacrylate-stilbene (MOAS) mobilize the
ISP-ED whereas Class Ib inhibitor (stigmatellin) and Class Ic inhibitor
(UHDBT) ﬁx the ISP-ED at the b-position (Table 2) [23]. Apparently, theTable 2
Conformational changes in the cd1 helix, the PEWY motif of cyt b and ISP subunits upon in
rmsd for Cα
Inhibitor-bound structure Inhibitor class [2Fe2S]⁎ anomalous peak Cyt b (3–379
Native⁎⁎ 0.52 –
Azoxystrobin Pm 0.36 0.26
Myxothiazol Pm 0.46 0.26
MOAS Pm 0.23 0.23
Famoxadone Pf 1.02 0.33
UHDBT Pf 0.96 0.40
Stigmatellin Pf 1.20 0.33
JG144 Pf 1.17 0.28
NQNO PN 0.83 0.33
Stig-yeast Pf – –
Antimycin A N 0.51 0.31
⁎Normalized anomalous difference Fourier peaks for the Fe atoms in the ISP subunit [26].
†rmsds in Å between cyt b subunits of inhibitor-bound and native bc1 complex.
‡Distance between residues either in the same subunit or in different subunits. Superscript
§Residues included in the calculation are 141–160, 167–170, and 263–270 of the cyt b subun
¶CA between ISP and cyt b. The CA is calculated by using the ISP extrinsic domain only (71–
||Surface complementarity [32].
⁎⁎Native coordinates are from Protein Data Bank ID code 1NTM [33].
††The chemical structure of JG144 is S-3-anilino-5-methyl-5-(4,6-diﬂuorophenyl)-1,3-oxazo
‡‡Obtained from Ref. [13].
§§Obtained from Ref. [31].conformation of ISP-ED can undergo a binary switch from a ﬁxed state
to a mobile state. Furthermore, while all QP inhibitors were found
binding to the same pocket, two inhibitor-binding sites within the
pocket were revealed. The site for myxothiazol and MOA-stilbene is
close to the bL heme and the one for stigmatellin andUHDBT is near the
2Fe2S cluster (Fig. 3). In the sequential bifurcated ETmechanism at the
QP site (Fig. 1A), it was proposed that an ubiquinol substrate binds
transiently to the stigmatellin/UHDBT binding site (P1) and a
ubisemiquinone takes the myxothiazol/MOAS binding site (P2).
Electron bifurcation can be achieved when a quinol at P1 site traps
the ISP-ED at the b-site and transfers the ﬁrst electron to ISP. As long as
ISP-ED is at the b-site, the reduced ISP is not able to transfer its electron
to c1 due to the distance constraint. The resulting ubisemiquinone
moves to the P2 site, forcing the transfer of the second electron to the
bL heme, then to the bH heme sequentially and releasing the ISP-ED to
the mobile state. The ISP-ED in the mobile state is capable of moving
close to the cyt c1 for electron delivery. Although this sequential
mechanism utilized for the ﬁrst time the two conformations of ISP-ED,
the absence of a detectable ubisemiquinone radical undermines its
validity [7], even though unusual radicals have been reported under
strange conditions [24,25].
5. Pre-steady state ultra-fast kinetics shows that cyt bL reduction
is faster than cyt c1 reduction
The pre-steady state kinetic analysis of cyt bL and ISP, using an ultra-
fast microﬂuidic mixer and a freeze-quenching device, coupled with
EPR, indicates that both cyt bL and ISP are reduced by ubiquinol at the
same rate [7]. No ubisemiquinone radical is detected in theﬁrst phase of
cyt bL and ISP reduction within 100 μs. The reduction of cyt bH occurs
before the reduction of cyt c1. Since the reduction of ISP by ubiquinol
takes place when ISP-ED is located at the b-position, a movement of
head domain to the c-position is mandated in order to be able to
transfer its electron to the cyt c1. It was speculated that the
conformational change of cyt b subunit resulting from the ET from
the reduced cyt bL to cyt bH provides a favorable environment that
enables ISP-ED to move from the b-position to c1-position for the
reduction of cyt c1. This mechanism is an extension of “catalytic switch”
hypothesis proposed by Brandt et al. [22] before the availability of the
structural information of the bc1 complex.hibitor binding
, †Å Displacement relative
to the native, ‡Å
Changes in
binding of ISP
to cyt b
) Qo site § 32 residues bI146 Cα bP270Cα bS151Cα CA,¶ (Å2) SC||
– 0.0 0.0 0.0 – 0.55
0.72 −0.76 1.81 −0.71 −86 0.39
0.81 −0.57 1.66 –0.71 −69 0.38
0.59 −0.35 1.62 −0.42 −78 0.39
0.91 +0.87 1.96 +0.58 65 0.60
1.11 +1.73 0.72 +0.60 129 0.60
1.32 +1.61 1.58 +0.96 92 0.60
0.81 +1.06 1.86 +0.52 79 0.59
0.59 – – – 56 0.61
– – – – – –
0.59 +0.34 0.24 −0.15 – –
letter on the left denotes subunit; subscript on the right is for atom type.
it.
196). The native (apo) protein has a CA of 356 Å2.
lidine-2,4-dione.
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Based on ten well reﬁned crystal structures of bovine bc1 with or
without bound inhibitors (Table 2), a modiﬁed classiﬁcation scheme
for bc1 inhibitors was proposed [26].
Inhibitors that bind to the QN pocket are called N type inhibitors;
those that go to theQP pocket are termed P inhibitors. Subclasses for the
P-type inhibitors are also deﬁned. P-type inhibitors that bind to the site
close to 2Fe2S cluster and ﬁx the ISP-ED conformation are referred to as
Pf inhibitors; those that bind near the bL heme andmobilize the ISP-ED
are termed Pm inhibitors. Structures of all Pm inhibitors contain a
common β-methoxyacrylate (MOA) group or its derivatives. Pf
inhibitors are much more diverse structurally, some of them bearing
resemblance to the substrate ubiquinone. Most importantly, the
structures of bc1 in complex with oxazolidinedione fungicides such as
famoxadone and JG144 [27,28] demonstrate that binding of ISP-ED to
the cyt b subunit at the b-site is an intrinsic property of the bc1
complex; it is independent of the hydrogen bond between the ISP-ED
and the bound inhibitors/substrate as previously proposedbased on the
structures of bc1 with bound stigmatellin [12,13] and HHDBT [29],
because in the complex structures of bc1 with bound famoxadone and
JG144, there is no direct hydrogen bonding between the bound
inhibitor and the ISP-ED yet the ISP-ED is still tightly bound at the b-site.
7. The bi-directional movement of the cd1 helix in cyt b controls
the conformational switch of ISP-ED
The question of how the cyt b subunit controls the ISP-ED motion
switch was addressed by Esser et al. by comparing reﬁned bovine bc1
structures in the presence or absence of inhibitors (Table 2) [28]. The
shape of the ISP-ED binding site on cyt b resembles a volcanic crater,
hence the ISP binding crater (Fig. 4A), which is contributed by residues
from the cd1 helix and those from the EF loop centered on the PEWY
motif (Fig. 4B). Both the cd1 helix and the PEWY motif are of the two
most conserved sequencemotifs in the cyt b subunit. The cd1 helix lies
parallel to the membrane plane. Movements are seen in both the cd1
helix and the PEWY motif upon the binding of inhibitors. Structure
alignments of various inhibitor complexes showed thatwhile the PEWY
motif moves unidirectionally, the direction of the cd1 helix movement
depends on the types of inhibitor bound. The Pf inhibitorsmove the cd1
helix in a direction that makes the ISP binding crater bigger and better
ﬁts the ISP-ED. The Pm inhibitors drive the cd1 helix in an opposite
direction that makes the ISP-ED ﬁt less well (Fig. 4C). Therefore, by
controlling the direction of the cd1 helix motion, the cyt b subunit is
able to effectively change the afﬁnity for the binding of the ISP-ED.
8. The mechanism for control of the ISP-ED movement during
catalytic cycle
It has been speculated, in the previous section, that the protein (cyt
b) conformational change caused by the electron transfer fromheme bL
to heme bH within the cyt b subunit facilitates the movement of ISP-EDFig. 4. ISP-ED binding crater and control of ISP-ED motion switch. (A) van der Waals
surface representation of the cyt b and ISP subunit in the bc1 complex viewed along the
membrane plane. The cyt b subunit is in gray and the ISP subunit is yellow. The cd1 helix
of cyt b subunit is colored magenta and the bound stigmatellin is shown as the CPK
model with carbon atoms in black and oxygen in red. The hinge region of the ISP is
colored in blue. (B) View of the ISP-ED binding surface down from the inter-membrane
space. The residues in cyt b subunit, which are in contact with the ISP-ED, are painted
cyan. The bound stigmatellin are shown as CPK model. The positions of the structural
motifs such as ef helix, cd1, and cd2 are indicated. (C) Schematic representation of the bi-
directional motion of the cd1 helix. Two structures are represented here: one bound
with Pm inhibitor azoxystrobin and another with bound Pf inhibitor famoxadone. Both
are shown as stick models and colored in yellow and cyan, respectively. The cd1 helix in
the famoxadone structure is blue and that in the azoxystrobin structure is red. The 2Fe2S
cluster and its ligand are bound at the b-site derived from the famoxadone structure.[7,30]. This speculation is supported by the fact that reduction of heme
bH occurs before the reduction of heme c1. However, the question of
how cyt b controls the ISP-ED movement during catalytic cycle has not
been addressed with experimental evidence until now.
Fig. 5. Time dependent inhibitory efﬁcacy of stigmatellin or MOAS on cyt bc1 complex at
different redox state. Five micromolar cyt bc1 complex in fully oxidized (o), ascorbate-
reduced (×) or succinate-reduced (Δ) state was incubated with 3 μM stigmatellin (A) or
MOAS (B). The activities of incubated samples were determined at various incubation
times. The activity of sample incubated with no inhibitor was used as time zero.
1042 C.-A. Yu et al. / Biochimica et Biophysica Acta 1777 (2008) 1038–1043One likelymechanism is the redox induced conformational changes
of cyt b. This mechanism can be tested by examining the redox state
dependent inhibitory efﬁcacy and inhibitor-binding afﬁnity of Pm and
Pf, since these two types of inhibitors can induce different conforma-
tions of cyt b, one conformation retains ISP-ED at the b-position and
other facilitates ISP-ED movement. If this mechanism prevails, we
would expect to see that the bc1 with its ISP-ED in a ﬁxed conformation
displays a higher inhibitory efﬁcacy and binding afﬁnity for Pf in-
hibitors. Likewise, the bc1 complex with its cyt b conformation that
facilitates ISP-ED movement will bind Pm inhibitors better.
In order to compare the inhibitory efﬁcacy of a given inhibitor under
the different redox states of the cyt bc1 complex. The concentration of
the inhibitor used must be less than that causes 100% inhibition at
sufﬁcient incubation time. Thus, a titration of cyt bc1 complex with a Pf
inhibitor, stigmatellin, and a Pm inhibitor, MOAS, was carried out to
determine the inhibitor concentration used. The concentration of
inhibitors that inhibit 60–70% of the bc1 activity after incubation at 0 °C
for 15 min was selected. The cyt bc1 complex (5 μM cyt c1) at various
redox states (oxidized, ascorbate-reduced, and succinate-reduced) was
treated with 3 μM of stigmatellin or MOAS and incubated at 0 °C. At
different time intervals, aliquots were withdrawn from each treated
sample and assayed for bc1 activity. The activity of the sample with no
addition of inhibitor was used as 0 incubation time and as 100%.
As shown in Fig. 5A, stigmatellin has higher inhibitory efﬁcacy
when it incubated with the cyt bc1 complex having its cyt c1 and ISP in
the reduced state (ascorbate-reduced) as compared to that incubated
with oxidized complex, suggesting that when cyt c1 and ISP are in
reduced state, the complex (cyt b) is in a conformation that restrains
the movement of ISP-ED.
On the other hand, when the cyt bc1 complex having its cyt bH in
the reduced state (succinate-reduced), the inhibitory efﬁcacy of MOAS
(see Fig. 5B) is higher than that in the ascorbate-reduced or oxidized
state, suggesting that when cyt bH is in the reduced state the
movement of ISP-ED is facilitated. It should be noted that reduction of
cyt bH in the bc1 complex by succinate was achieved by addition a
catalytic amount of succinate-cyt c reductase to the sample. A 1 h
incubation with 10 mM succinate is needed in order to reduce cyt bH
completely.
Since both ascorbate and succinate-reduced cyt bc1 complexes
have their cyt c1 in the reduced state, the difference in the inhibitor
efﬁcacy observed might be complicated by the reduced state of cyt c1.
To avoid this complication, cyt bc1 complex with only ISP in reduced
statewas prepared and used. The cyt bc1 complex was ﬁrst reduced by
a limited amount of ascorbate to 50% cyt c1 reduction, at pH 8.0. The
pH of the partially reduced complex was then adjusted back to 7.0.
Under this condition, ISP is mostly reduced and cyt c1 is mostly
oxidized [31]. When this bc1 preparation was used for inhibitory
efﬁcacy test, it was found that the inhibitory efﬁcacy of stigmatellin is
similar to that of the complex inwhich ISP and cyt c1 are both reduced,
indicating that the redox state of cyt c1 has little contribution to the Pf
inhibitor binding. Although the presence of reduced cyt c1 in the
ascorbate-reduced complex does not affect the inhibitory efﬁcacy of
stigmatellin, the reduced cyt c1 in succinate-reduced complex would
be more complicated, as both ISP and bH are in the reduced form, the
former would enhance stigmatellin binding and later would decrease
the binding. As shown in Fig. 5A the inhibitory efﬁcacy of stigmatellin
to succinate-reduced complex is slightly lower than that to the
ascorbate-reduced complex but much higher than that to the oxidized
complex.
To further conﬁrm that binding afﬁnity of Pm and Pf inhibitors to
the cyt bc1 complex is redox states dependent, the binding afﬁnity of
stigmatellin and MOAS to different redox states of the bc1 complex
were determined by isothermo calorimetric titration. MOAS binds
twice stronger to the succinate-reduced state than to the oxidized or
ascorbate-reduced complex. On the other hand stigmatellin binds
better to the ascorbate-reduced state than to the oxidized state. Theseresults are consistent with the inhibitory efﬁcacies described in the
previous section.
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